|
Age (year, x ± s)
|
59.2 ± 15.6
|
61.4 ± 13.1
|
0.31
|
|
Male (n (%))
|
138 (96.5)
|
59 (100)
|
0.15
|
|
Caucasian (n (%))
|
128 (89.5)
|
57 (96.6)
|
0.10
|
|
History of psychiatric disorder (n (%))
|
74 (51.7)
|
42 (71.2)
|
0.01
|
|
Type of IBD (n (%))
| | |
< 0.001
|
|
Crohn’s disease
|
78 (54.5)
|
48 (81.4)
| |
|
Ulcerative colitis
|
65 (45.5)
|
11 (18.6)
| |
|
Duration of IBD (year, median(IQR))
|
16 (7-30)
|
16 (3-34)
|
0.84
|
|
History of bowel resection (n (%))
|
95 (66.4)
|
39 (66.1)
|
0.96
|
|
IBD medication prior to admission (n (%))
|
|
5-ASA
|
51 (35.7)
|
15 (25.4)
|
0.16
|
|
Immunomodulator (AZA/6-MP or MTX)
|
29 (20.3)
|
15 (25.4)
|
0.42
|
|
Anti-TNF
|
18 (12.6)
|
6 (10.2)
|
0.63
|
|
Steroids
|
25 (17.5)
|
15 (25.4)
|
0.20
|
|
Psychiatric/pain medication prior to admission (n (%))
|
|
Benzodiazepine
|
24 (16.8)
|
9 (15.3)
|
0.79
|
|
Narcotics
|
57 (39.9)
|
28 (47.5)
|
0.32
|
|
Antidepressant
|
47 (32.9)
|
33 (55.9)
|
0.002
|
|
Medication at discharge (n (%))
|
|
Change in IBD medication at discharge
|
32 (22.4)
|
23 (39)
|
0.02
|
|
Benzodiazepine at discharge
|
22 (15.4)
|
8 (13.6)
|
0.74
|
|
Narcotics at discharge
|
75 (52.4)
|
29 (49.2)
|
0.67
|
|
Discharge to home (n (%))
|
135 (94.4)
|
51 (86.4)
|
0.06
|
|
Complication during hospitalization (n (%))
|
|
Surgical procedures during admission
|
28 (19.6)
|
10 (16.9)
|
0.66
|
|
ICU stay
|
6 (4.2)
|
3 (5.1)
|
0.78
|
|
Nosocomial infection
|
6 (4.2)
|
2 (3.4)
|
0.79
|
|
Venous thromboembolism
|
1 (0.7)
|
1 (1.7)
|
0.52
|
|
Length of hospitalization (day, median (IQR))
|
4 (2-6)
|
4 (2-8)
|
0.84
|
|
Follow-up after hospitalization (n (%))
|
|
Mention of follow-up with PCP in discharge summary/nurse note
|
71 (49.7)
|
32 (54.2)
|
0.55
|
|
Follow-up with PCP clinic within 90 days
|
74 (51.7)
|
16 (27.1)
|
0.001
|
|
Mention of follow-up with GI in discharge summary/nurse note
|
67 (46.9)
|
31 (52.5)
|
0.46
|
|
Follow-up in GI clinic within 90 days
|
67 (46.9)
|
18 (30.5)
|
0.03
|
